459 related articles for article (PubMed ID: 15479866)
1. Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004.
Furst DE; Breedveld FC; Kalden JR; Smolen JS; Burmester GR; Bijlsma JW; Dougados M; Emery P; Keystone EC; Klareskog L; Mease PJ
Ann Rheum Dis; 2004 Nov; 63 Suppl 2(Suppl 2):ii2-ii12. PubMed ID: 15479866
[No Abstract] [Full Text] [Related]
2. Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005.
Furst DE; Breedveld FC; Kalden JR; Smolen JS; Burmester GR; Bijlsma JW; Dougados M; Emery P; Keystone EC; Klareskog L; Mease PJ
Ann Rheum Dis; 2005 Nov; 64 Suppl 4(Suppl 4):iv2-14. PubMed ID: 16239380
[No Abstract] [Full Text] [Related]
3. [Current therapy with TNFalpha blocking agents for ankylosing spondylitis and undifferentiated spondyloarthritis].
Brandt J; Sieper J; Braun J
Z Rheumatol; 2004 Jun; 63(3):203-10. PubMed ID: 15224223
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic interleukin (IL) 1 blockade normalises increased IL1 beta and decreased tumour necrosis factor alpha and IL10 production in blood mononuclear cells of a patient with CINCA syndrome.
Seitz M; Kamgang RK; Simon HU; Villiger PM
Ann Rheum Dis; 2005 Dec; 64(12):1802-3. PubMed ID: 16284353
[No Abstract] [Full Text] [Related]
5. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.
Furst DE; Breedveld FC; Kalden JR; Smolen JS; Burmester GR; Emery P; Keystone EC; Schiff MH; van Riel PL; Weinblatt ME; Weisman MH
Ann Rheum Dis; 2006 Nov; 65 Suppl 3(Suppl 3):iii2-15. PubMed ID: 17038465
[No Abstract] [Full Text] [Related]
6. Safety of tumour necrosis factor and interleukin-1 blocking agents in rheumatic diseases.
Botsios C
Autoimmun Rev; 2005 Mar; 4(3):162-70. PubMed ID: 15823502
[TBL] [Abstract][Full Text] [Related]
7. Advances in targeted therapies X. Preface.
Breedveld FC; Kalden JR; Smolen JS
Ann Rheum Dis; 2008 Dec; 67 Suppl 3():iii1. PubMed ID: 19022807
[No Abstract] [Full Text] [Related]
8. Results of anakinra treatment in rheumatoid arthritis patients previously treated with tumor necrosis factor alpha blockade: comment on the article by Buch et al.
Saxne T; Larsson L; Geborek P
Arthritis Rheum; 2004 Sep; 50(9):3049-50; author reply 3050-1. PubMed ID: 15457477
[No Abstract] [Full Text] [Related]
9. Safety of anakinra, a recombinant interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis and comparison to anti-TNF-alpha agents.
Fleishmann RM
Clin Exp Rheumatol; 2002; 20(5 Suppl 27):S35-41. PubMed ID: 14989428
[TBL] [Abstract][Full Text] [Related]
10. Lack of response to anakinra in rheumatoid arthritis following failure of tumor necrosis factor alpha blockade: comment on the article by Buch et al.
Schiff MH
Arthritis Rheum; 2005 Jan; 52(1):364-5; author reply 365. PubMed ID: 15641081
[No Abstract] [Full Text] [Related]
11. Anakinra: the first interleukin-1 inhibitor in the treatment of rheumatoid arthritis.
Kary S; Burmester GR
Int J Clin Pract; 2003 Apr; 57(3):231-4. PubMed ID: 12723729
[TBL] [Abstract][Full Text] [Related]
12. Kineret: efficacy and safety in daily clinical practice: an interim analysis of the Kineret response assessment initiative (kreative) protocol.
Langer HE; Missler-Karger B
Int J Clin Pharmacol Res; 2003; 23(4):119-28. PubMed ID: 15224501
[TBL] [Abstract][Full Text] [Related]
13. [Biological treatment of rare inflammatory rheumatic diseases].
Baslund B
Ugeskr Laeger; 2008 Jun; 170(24):2150-2. PubMed ID: 18565301
[TBL] [Abstract][Full Text] [Related]
14. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008.
Furst DE; Keystone EC; Kirkham B; Kavanaugh A; Fleischmann R; Mease P; Breedveld FC; Smolen JS; Kalden JR; Burmester GR; Braun J; Emery P; Winthrop K; Bresnihan B; De Benedetti F; Dörner T; Gibofsky A; Schiff MH; Sieper J; Singer N; Van Riel PL; Weinblatt ME; Weisman MH
Ann Rheum Dis; 2008 Dec; 67 Suppl 3():iii2-25. PubMed ID: 19022808
[No Abstract] [Full Text] [Related]
15. [Biological treatment of rheumatic diseases].
Procházková L; Böhmová J; Soucek M
Vnitr Lek; 2006 Jun; 52(6):632-9. PubMed ID: 16871769
[TBL] [Abstract][Full Text] [Related]
16. Biologics in rheumatoid arthritis.
Sharma PK; Hota D; Pandhi P
J Assoc Physicians India; 2004 Mar; 52():231-6. PubMed ID: 15636315
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-1beta influences the effect of infliximab on temporomandibular joint pain in rheumatoid arthritis.
Kopp S; Alstergren P; Ernestam S; Nordahl S; Bratt J
Scand J Rheumatol; 2006; 35(3):182-8. PubMed ID: 16766364
[TBL] [Abstract][Full Text] [Related]
18. Ankylosing spondylitis: new treatment modalities.
Brandt J; Marzo-Ortega H; Emery P
Best Pract Res Clin Rheumatol; 2006 Jun; 20(3):559-70. PubMed ID: 16777582
[TBL] [Abstract][Full Text] [Related]
19. The trials of anakinra.
Burls A; Jobanputra P
Lancet; 2004 Sep 4-10; 364(9437):827-8. PubMed ID: 15351176
[No Abstract] [Full Text] [Related]
20. [Tolerance of anti-TNF alpha: the experience acquired in inflammatory rheumatic disease].
Mariette X
Ann Dermatol Venereol; 2006 May; 133(5 Pt 2):1S8-12. PubMed ID: 16967603
[No Abstract] [Full Text] [Related]
[Next] [New Search]
